Reneo Pharmaceuticals Inc (RPHM)
1.72
+0.06
(+3.61%)
USD |
NASDAQ |
May 17, 16:00
1.70
-0.02
(-1.16%)
After-Hours: 20:00
Reneo Pharmaceuticals SG&A Expense (Quarterly): 4.622M for March 31, 2024
SG&A Expense (Quarterly) Chart
Historical SG&A Expense (Quarterly) Data
| Date | Value |
|---|---|
| March 31, 2024 | 4.622M |
| December 31, 2023 | 7.402M |
| September 30, 2023 | 7.266M |
| June 30, 2023 | 6.639M |
| March 31, 2023 | 5.132M |
| December 31, 2022 | 4.205M |
| September 30, 2022 | 3.902M |
| June 30, 2022 | 4.299M |
| March 31, 2022 | 3.737M |
| Date | Value |
|---|---|
| December 31, 2021 | 3.524M |
| September 30, 2021 | 3.434M |
| June 30, 2021 | 2.949M |
| March 31, 2021 | 1.742M |
| December 31, 2020 | 1.133M |
| September 30, 2020 | 0.668M |
| June 30, 2020 | 0.882M |
| March 31, 2020 | 0.924M |
SG&A Expense Definition
SG&A expense (short for Selling, General and Administrative expense) is a line item on the income statement, though sometimes sales and marketing expenses are reported separately from general and administrative expenses.
SG&A Expense (Quarterly) Range, Past 5 Years
0.668M
Minimum
Sep 2020
7.402M
Maximum
Dec 2023
3.674M
Average
3.737M
Median
Mar 2022
SG&A Expense (Quarterly) Benchmarks
| Mirum Pharmaceuticals Inc | 45.64M |
| NovaBay Pharmaceuticals Inc | 3.346M |
| Palatin Technologies Inc | 2.033M |
| iBio Inc | 2.961M |
| Theriva Biologics Inc | 1.933M |